← Russell 3000 cross-section

STIM Neuronetics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$226m
Revenue TTM
$155m
Net income TTM
$-30m
Free cash flow
$-11m
Composite score
34.2
Sector rank
#2813

Valuation

P / E
EV / EBITDA
EV / sales
1.7
FCF yield
-4.98%
Earnings yield vs 10-yr
-18.19pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-19.6%
EBITDA margin
-12.7%
ROE
-170.5%
ROIC
-38.0%
Revenue growth
39.6%

Insider activity, last 90 days

Net open-market
$0.11m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For the three months ended June 30, 2026, our Greenbrook revenue and our NeuroStar revenue represented 65% and 35% of our revenues, respectively. For the six months ended June 30, 2026, Greenbrook revenue and our NeuroStar revenue represented 64%and 36% of our revenues, respectively. Total revenues increased by $3.5 million, or 9%, from $38.1 million for the three months ended June 30, 2025 to $41.6 million for the three months ended June 30, 2026 and increased by $5.9 million, or 8%, from $70.1 million for the six months ended June 30, 2025 to $76.0 million for the six months ended June 30, 2026. The increase was primarily attributable to an increase in Greenbrook revenue. …Neuronetics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →